Lead Program

About MatriSys Bioscience

MatriSys Bioscience is a private, pre-revenue biotech company leveraging a proprietary discovery platform to develop topical live biotherapeutics from beneficial skin bacteria. Its lead program targets atopic dermatitis, with additional candidates for acne, Netherton syndrome, and other disorders, addressing a significant unmet need in dermatology. The company is led by a seasoned team with strong scientific roots in skin immunology and microbiome research from UCSD and extensive drug development experience. MatriSys aims to reduce reliance on steroids and immunosuppressants by restoring the natural skin microbiome.

About Elastrin Therapeutics

Elastrin Therapeutics is a private, preclinical-stage biotech founded in 2017 and based in Greenville, USA, pioneering a first-in-class approach to reverse arterial calcification. Its core technology is a targeted nanoparticle that delivers therapeutic agents directly to damaged elastin, aiming to dissolve pathological calcification non-invasively. The company is targeting a massive global market, starting with over 200 million patients suffering from Peripheral Artery Disease, where calcification is a major driver of morbidity. If successful, Elastrin's therapy could transform the treatment landscape for a wide range of cardiovascular conditions currently lacking effective disease-modifying options.

About TippingPoint Biosciences

TippingPoint Biosciences is a private, pre-clinical stage biotech developing first-in-class therapeutics targeting aberrant chromatin networks, a root cause of many cancers and genetic diseases. The company's proprietary platform aims to drug previously 'undruggable' unstructured protein interfaces unique to disease states, potentially offering greater specificity and reduced toxicity compared to existing chromatin-targeting approaches. Backed by mission-aligned investors like the Pediatric Brain Tumor Foundation and the American Cancer Society's BrightEdge, TippingPoint is advancing its lead program for pediatric brain tumors while building a pipeline for other chromatin dysfunction diseases. The company combines deep academic expertise in chromatin biology from UCSF with seasoned drug discovery and development leadership from the biopharma industry.

Therapeutic Areas

Other Atopic Dermatitis Drugs